Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134(16): 813-817
DOI: 10.1055/s-0029-1220236
DOI: 10.1055/s-0029-1220236
Aktuelle Diagnostik & Therapie | Review
article
Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York
Diagnostik und Therapie bei schwer einstellbarer Hypertonie
Diagnostic procedures and treatment in patients with resistant hypertensionFurther Information
Publication History
eingereicht: 3.3.2009
akzeptiert: 24.3.2009
Publication Date:
07 April 2009 (online)
Schlüsselwörter
schwer einstellbare Hypertonie - Non-Compliance - sekundäre Hypertonieformen
Keywords
resistant hypertension - non-compliance - secondary hypertension
Literatur
- 1 Anderson Jr G H, Blakeman N, Streeten D H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994; 12 609-15
- 2 Berlowitz D R, Ash A S, Hickey E C, Friedman R H, Glickman M, Kader B, Moskowitz M A. et al . Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339 1957-63
- 3 Brown M A, Buddle M L, Martin A. Is resistant hypertension really resistant?. Am J Hypertens. 2001; 14 1263-9
- 4 Calhoun D A, Jones D, Textor S, Goff D C, Murphy T P, Toto R D, White A, Cushman W C, White W, Sica D, Ferdinand K, Giles T D, Falkner B, Carey R M. American Heart Association Professional Education Committee . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117 e510-26
- 5 Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo Jr J L, Jones D W, Materson B J, Oparil S, Wright Jr J T, Roccella E J. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the JNC 7 report. JAMA. 2003; 289 2560-72
- 6 Cuspidi C, Macca G, Sampieri L. et al . High prevalence of cardiac and extracardiac organ damage in refractory hypertension. J Hypertens. 2001; 19 2063-70
- 7 Dickerson J EC, Hingorani A D, Ashby M J, Palmer C R, Brown M J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999; 353 2008-13
- 8 Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England. Results from the Health Survey for England 2006. Hypertension. 2009; 53 480-6
- 9 Gonzaga C C, Calhoun D A. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008; 10 496-503
- 10 Hajjar I, Kotchen T A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1998 – 2000. JAMA. 2003; 290 199-206
- 11 Hausberg M, Mann J, Kühn K. Nieren und Hochdruck. Dtsch Med Wochenschrift. 2008; 133 1853-1856
- 12 Hyman D J, Pavlik V N. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001; 345 479-86
- 13 Jackson K C, Sheng X, Nelson R E, Keskinasian A, Brixner D I. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008; 30 1558-63
- 14 Lehnert H, Scholz T, Schäfer M, Klose S. Endokrine Hochdruckformen. Dtsch Med Wochenschrift. 2007; 132 207-217
- 15 Lloyd-Jones D M, Evans J C, Larson M G, O’Donnel C J, Rocella E J, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000; 36 594-599
- 16 Mann J F, Schmieder R E, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas L S, Svendsen T L, Teo K K, Yusuf S. ONTARGET investigators . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372 547-53
- 17 Mann S J. Severe paroxysmal hypertension (pseudopheochromocytoma). Arch Intern Med. 1999; 159 670-4
- 18 Moser M, Setaro J F. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355 385-92
- 19 Nuesch R, Schroeder K, Dieterle T, Benedeict M, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ. 2001; 323 142-146
- 20 Oparil S, Calhoun D A. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998; 57 1007-14
- 21 Sarafidis P A, Bakris G L. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52 1749-57
- 22 Vinker S, Alkalay A, Hoffman R D, Elhaynay A, Kaiserman I, Kitai E. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin Pharmacother. 2008; 9 1271-7
- 23 Zeller A, Schroeder K, Peters T J. Alectronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care. Scand J Prim Health Care. 2007; 25 2002-7
Prof. Dr. med. J. Hoyer
Direktor der Klinik für Innere Medizin und
Nephrologie, Universitätsklinikum Gießen
und Marburg GmbH, Standort Marburg
Baldingerstraße
35033 Marburg
Email: hoyer@med.uni-marburg.de